Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01776437 · ClinicalTrials.gov registry record · Phase 1

Study of BMN 673, a PARP Inhibitor, in Healthy Adult Male Volunteers

A Phase 1 study, sponsored by Pfizer.

Completed
Registry status
Phase 1
Development phase
18
Enrollment target

NCT01776437 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 18 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01776437, a Phase 1 study, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
18 participants
Enrollment target

Study Summary

This is a randomized, 2-period, 2-sequence crossover study to evaluate the effect of food on the relative bioavailability of BMN 673 during fasting and fed conditions in healthy male subjects.

Interventions

  • DRUG BMN 673

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2013-02
Est. Completion 2013-07
Phase Phase 1

Sponsor

Pfizer

1,845 total trials

What the Registry Record Tells You About NCT01776437

The ClinicalTrials.gov registry entry for NCT01776437 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which BMN 673 is the first listed.

NCT01776437 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01776437 about?

NCT01776437 is a clinical study titled "Study of BMN 673, a PARP Inhibitor, in Healthy Adult Male Volunteers". This is a randomized, 2-period, 2-sequence crossover study to evaluate the effect of food on the relative bioavailability of BMN 673 during fasting and fed conditions in healthy male subjects.

What is the current status of trial NCT01776437?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2013-02. Estimated completion is 2013-07.

What interventions are being tested in trial NCT01776437?

The interventions under investigation include: BMN 673 (DRUG).

Who is sponsoring clinical trial NCT01776437?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.